Table 2 Association between organ-by-organ baseline ESSDAI activity at diagnosis and the risk of development of solid and hematological cancer
From: Characterization and risk estimate of cancer in patients with primary Sjögren syndrome
Variables | Values at diagnosis (n = 1295)a | Solid cancer (n = 70) | Hematological cancer (n = 61) |
|---|---|---|---|
Baseline DAS | |||
Low | 707 (54.6) | REF | REF |
Moderate | 426 (32.9) | 1.17 [0.71–1.92] | 1.37 [0.73–2.58] |
High | 162 (12.5) | 0.66 [0.28–1.56] | 4.34 [2.35–8.00] |
ESSDAI domains† | |||
Constitutional | 115 (8.9) | 1.13 [0.48–2.62] | 2.44 [1.23–4.87] |
Lymphadenopathy | 89 (6.9) | 0.39 [0.10–1.60] | 8.03 [4.62–13.94] ‡ |
Glandular | 179 (13.8) | 0.35 [0.14–0.87] | 3.04 [1.78–5.18] ‡ |
Articular | 498 (38.5) | 0.95 [0.58–1.56] | 1.30 [0.78–2.18] |
Cutaneous | 131 (10.1) | 1.40 [0.70–2.83] | 1.10 [0.47–2.57] |
Pulmonary | 102 (7.9) | 1.58 [0.71–3.48] | 1.07 [0.38–2.99] |
Renal | 23 (1.8) | 1.21 [0.17–8.80] | – |
Muscular | 15 (1.2) | 1.57 [0.22–11.4] | – |
Peripheral nervous system | 54 (4.2) | 0.59 [0.14–2.45] | – |
Central nervous system | 41 (3.2) | – | 0.44 [0.06–3.22] |
Hematological | 447 (34.5) | 1.31 [0.81–2.10] | 1.36 [0.81–2.26] |
Biological | 681 (52.6) | 1.32 [0.81–2.15] | 2.12 [1.19–3.76] |